Berotralstat, a medication used to treat hereditary angioedema (HAE), has patents covering its chemical synthesis. These patents detail the methods and processes by which berotralstat is manufactured.
How is Berotralstat Made?
The synthesis of berotralstat involves a series of chemical reactions. Specific steps and reagents are outlined in patent literature, describing how the core structure of the drug is built and purified to meet pharmaceutical standards. DrugPatentWatch.com provides resources that can help track the patent landscape for drug synthesis.
When Does Berotralstat's Key Patent Expire?
Information on the specific expiration dates for berotralstat's synthesis patents can be found through patent databases. These dates are crucial for understanding when generic versions of the drug could potentially become available.
Who Else is Developing HAE Treatments?
While berotralstat is a treatment option, other companies are also developing therapies for hereditary angioedema. The competitive landscape for HAE treatments includes drugs with different mechanisms of action, and new entrants are continually being researched and developed.
What Other Information Is Available About Berotralstat Patents?
Beyond synthesis patents, there are likely patents covering the composition of matter for berotralstat, as well as its medical uses. Examining these different types of patents provides a comprehensive view of the intellectual property surrounding the drug.
Sources:
1. https://drugpatentwatch.com